The Role of Vascular Endothelial Growth Factor A Polymorphisms in Breast Cancer

The single-nucleotide polymorphisms +936 C/T VEGF and −710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population

(2012) Patricia Rodrigues et al.   BREAST CANCER RESEARCH AND TREATMENT

First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study

(2012) Christoph Thomssen et al.   ONCOLOGY

Evaluation of Functional Genetic Variants for Breast Cancer Risk: Results From the Shanghai Breast Cancer Study

(2011) B. Zhang et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Genetic Variation in VEGF Family Genes and Breast Cancer Risk: A Report from the Shanghai Breast Cancer Genetics Study

(2011) A. Beeghly-Fadiel et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: A meta-analysis involving 16,703 individuals

(2011) Kai Wang et al.   CYTOKINE

Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis

(2010) Dae Sik Yang et al.   BREAST CANCER RESEARCH AND TREATMENT

VEGF 936C>T polymorphism and breast cancer risk: evidence from 5,729 cases and 5,868 controls

(2010) Dongying Gu et al.   BREAST CANCER RESEARCH AND TREATMENT

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients

(2010) Marie-Christine Etienne-Grimaldi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival

(2010) LaCreis R. Kidd et al.   CANCER CAUSES & CONTROL

Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer

(2010) Gudrun Knechtel et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case–control studies

(2010) Liu Liu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics

(2010) Cristiane Oliveira et al.   TUMOR BIOLOGY

The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women

(2008) Anna Jakubowska et al.   CANCER LETTERS

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

(2008) H. J. Burstein et al.   CLINICAL CANCER RESEARCH

Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?

(2008) Anna Jakubowska et al.   EUROPEAN JOURNAL OF CANCER

High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer

(2008) Sriparna Ghosh et al.   HUMAN PATHOLOGY

Study on relationship between angiogenesis and micrometastases of peripheral blood in breast cancer

(2008) Xiao-Dong Xie et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY